In terms of pharmaceutical business, the domestic pharmaceutical economy continued to develop well in 20 10. The pharmaceutical group actively explored the market to increase sales, strengthened internal management to reduce costs and fees, and maintained the double growth momentum of revenue and profit. Through active and orderly drug bidding, the pharmaceutical group has ensured the continuous growth of sales of existing products and new products. In 20 10, the company's pharmaceutical sales revenue increased by 7.03% year-on-year, which reflected the pillar role of its core business. During the reporting period, the pharmaceutical group carried out technical transformation combined with GMP re-certification to further standardize production management. During the reporting period, Pharmaceutical Group obtained 1 new drug certificate, 2 production approvals, 6 new drug projects, 3 patent applications, 2 open patents and 2 patent authorizations. The research and development of endostatin, a key research and development project, is progressing smoothly, and the secondary development of existing products and the research and development of subsequent new products are also being carried out in batches, laying the foundation for the next step of variety structure adjustment. In addition, the first phase of the overall relocation project of Suzhou Sixth Pharmaceutical Factory, the existing key construction project of Pharmaceutical Group, has been successfully put into production, and the second phase is expected to complete GMP certification and put into production before the end of June 201/kloc-0. The main civil engineering of the API project has been completed, and the project equipment has been installed.
In terms of real estate business, the company resolutely implemented industrial restructuring and established real estate development and operation as an important development industry of the company. Although the whole real estate industry in 20 10 was greatly affected by the policy, the company's emerging real estate business still grasped the opportunity well. By building a real estate development platform, fully integrate the existing real estate business, comprehensively promote the construction and marketing of existing projects, make good reserves for subsequent new projects, actively respond to the adjustment of macro policies, lay a solid foundation, and create conditions for the sustainable operation of the company's real estate sector.
In terms of investment business, Xingrui Precious Metals, which is controlled by the company, actively adjusts the market layout and increases the development of high-quality customers in Suzhou's local self-operated terminals. All production and operation indicators have achieved great growth year on year.
In terms of management and control of enterprises under the headquarters, the company continues to adhere to the "enterprise management with system management as the core" model.
During the reporting period, the company further improved and perfected the internal control system, organized training, sorted out and improved the relevant internal control system, and strengthened the implementation of the internal control system in the company and industrial groups. The company has done a lot of work in information disclosure and investor relations management, audit supervision and financial management, corporate culture construction and talent strategic reserve, and achieved good results.
During the reporting period, the company cooperated with Qi Xin to improve the overall economic operation. During the reporting period, the company achieved operating income of 3,384,654.38+072,300 yuan, up 46.59% year-on-year, of which the main business income was 3,375,247,300 yuan, up 46.39% year-on-year. The operating profit (gross profit) was 30,236,543.8 yuan +0.97 million yuan, a year-on-year increase of 30.72%, of which the gross profit of main business was 293,985,300 yuan, a year-on-year increase of 28. 14%. The company realized a net profit of 29,306,5438 yuan +0.6 million yuan, a year-on-year increase of 65,438+0,065,438+0.15%.
According to the business plan made by the company in 20 10, it is planned to realize the main business income of 2.5 billion yuan in 20 10, and the proportion of main business cost in income is the same as that in 2009, so as to strive for a decrease. During the reporting period, the company's main business income was 3.375 billion yuan, exceeding the plan by 35%. The company's medicine, real estate and precious metal processing businesses all exceeded the plan, especially Suzhou Xingrui precious metal processing business achieved substantial growth (planned 654.38 billion+28 billion, actually completed 2.045 billion).
The above is the description of the company's development in 20 10. On this basis, you can do some strategic analysis, which should not be difficult. In the future, the company's cancer vaccine should be a key point of the company's performance outbreak, which can be analyzed emphatically.